2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
40
Gastro-enteropancreatic neuroendocrine tumor
8
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Stomach Neoplasms
1
Somatostatinoma
1
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Somatostatin Receptor-positive GEP-NET
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled